Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Summit Corporation LSE:SUMM London Ordinary Share GB00BN40HZ01 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.00p +0.00% 24.00p 11,938 08:00:00
Bid Price Offer Price High Price Low Price Open Price
23.00p 25.00p 24.00p 24.00p 24.00p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 25.40 -10.88 -10.56 38.5

Summit Corp (SUMM) Latest News

More Summit Corp News
Summit Corp Takeover Rumours

Summit Corp (SUMM) Share Charts

1 Year Summit Corp Chart

1 Year Summit Corp Chart

1 Month Summit Corp Chart

1 Month Summit Corp Chart

Intraday Summit Corp Chart

Intraday Summit Corp Chart

Summit Corp (SUMM) Discussions and Chat

Summit Corp (SUMM) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
12:43:1624.9615237.94O
11:11:0223.658,0831,911.63O
08:03:2823.653,703875.76O
View all Summit Corp trades in real-time

Summit Corp (SUMM) Top Chat Posts

DateSubject
16/1/2019
08:20
Summit Corp Daily Update: Summit Corporation is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SUMM. The last closing price for Summit Corp was 24p.
Summit Corporation has a 4 week average price of 17.50p and a 12 week average price of 17.50p.
The 1 year high share price is 242.50p while the 1 year low share price is currently 17.50p.
There are currently 160,389,881 shares in issue and the average daily traded volume is 45,336 shares. The market capitalisation of Summit Corporation is £38,493,571.44.
02/1/2019
12:41
wildbunch: Assuming no more dilution (a big, big if)then each £1bn of market cap = £6 share price. That is £3 for Mr Robert W Duggan and £3 for the rest of us. If drug works well and some of rest of pipeline works then market cap will be well north of £1bn. BUT lagosboy has a point- why would Duggan want to share with the rest of us if he can avoid that? The one thing in our favour is the 2.5m (approx) options @ 29.5p owned by our CEO. But one can imagine a scenario where the company is taken private with the CEO still employed with a new arrangement which leaves him no worse off. I can see Waterloo's point about current valuation being low on short term basis but am deeply sceptical about us being able to enjoy a potential a long term 30+ bagger. I am long term holder at average of around £1.5 so will continue for the ride!
28/12/2018
14:49
lagosboy: Deal with SRPT, that as way to late as you well know and was merely a punt heavily favouring SRPT for their own shareholders. In any event its dead now anyway, so how you reach the conclusion that is was a good deal is beyond my logic. By the time Summ get anything to market the bacteria will have mutated and it will be ineffective or have such a short useful life that no pharma will be interested anyway. Barda is a driven by political considerations as much as medical ones. Whoopee for Glyn, such a great deal that the share price has roared. As for cash- my point is $25m or whatever the figure is now for Summ is irrelevant in the context of the future funding that will be necessary. If Summ was sitting on a cash runway of $250m plus that would be a different matter. $25m will barely cover Glyn's salary, air travel and conference attendance!
28/12/2018
12:02
kirk 6: Why is the share price so incomprehensibly low? We now have a much greater cash position than mkp and a huge amount of news to look forward to in Q1 2019.?
19/12/2018
07:58
waterloo01: Thanks for that. Summit Therapeutics (SUMM) What have shares done? Summit has not had a good year. Shares fell off a cliff in June from 195p to 36.9p. They have recovered slightly to sit at 20.3p. What’s its current market cap? £14.8m. What was cash at last count? The company had cash and cash equivalents of £13m on 31 October 2018. However, earlier this week it announced that it would raise $25m by selling American Depositary Shares in a private placement. What’s next? As we have noted before, the biotech firm fell by as much as 80pc in July. This came after it revealed that it had discontinued its treatment for Duchenne Muscular Dystrophy. Despite this setback, the firm has been working to move forward. It is now focusing on the development of the three antibiotics left in its pipeline. This week, the business announced a whopping $25m placing. The funds will support a critical phase three clinical programme for ridinilazole. This is an antibiotic for colon infection C. Difficile. Unlike similar medications, it does not cause damage to natural gut flora during treatment. The money will also advance studies for the treatment of gonorrhoea. As Summit has demonstrated, investing in pharma businesses can be a bit like roulette. This is because these businesses often completely hang on the outcome of trials and the whim of regulators. If this is of interest, then Summit’s ambitious work programme could generate some significant share price movement.
22/11/2018
08:43
football: Quite ironic the days NASDAQ share price has been falling and we haven't moved in the one day it goes up we go down in the UK
20/9/2018
11:35
football: So basically the share price covers money in the bank and the funding we have already lined up and all the drugs we have in the pipeline for free going by market?
04/8/2018
17:52
the canadian mounted: Kirk6 is correct in thinking this price is achievable.current valuation of cash assets is not reflective of the company products currently in the pipeline. One failure does not deserve a 80% drop in share price,a re rating imo will occur soon.
30/7/2018
08:20
football: Hyper Al the link was a bit tongue in cheek and a very tenuous link to summit but does go to show the depths of project fear, I would of fought this movement of people would contain infectious diseases not the other way around. Anyway let's hope all director buys recently and the company focusing on this disease now news can't be far away along with a much-needed share price rise or rerating from here. Good luck
21/5/2018
12:27
luminoso: Thanks Hugus. It does not say much for the powers of research of the punters you describe from the nasdaq boards. Basically, those traders are pure momentum traders. If the share price is high, it must be good. If the share price is low, it must be bad ... or something does not add up. It also explains the share price of Sarepta at the moment. Of course many of these punters will be caught with their pants down, if Sarepta's share price implodes on fundamentals and Summit's share price explodes on likely approval of EZT. At some point, I expect Sarepta to make a move on EZT, either parts or the whole, as it will become increasingly clear to them that EZT is the most likely candidate around, currently, to make a difference to DMD boys. They have the cash still to achieve that but while the market sleeps with regard to EZT, they still have time before they have to make a move - around 48 week results time maybe ? The big question for me is - will they have any competition to acquire EZT the closer we get to results and, dare I say it, Approval ?
09/2/2018
14:21
hugus maximus: filmster .... well done, I should have sold some but was waiting for a NASDAQ share price hike that didn't materialise. Share price drop has deepened over past few days as the dollar / pound rate moved against us .... uk shares are dollar led ... aside from overall 4% drop in Biotech this week as a result of general share drift. There is nothing to suggest any negative news about the progress of either DMD P2 or C Diff at Summit.
Summit Corp share price data is direct from the London Stock Exchange
Your Recent History
LSE
SUMM
Summit Cor..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190116 17:21:41